首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2018年 11期 肝脏病理 => 其他 =>非诺贝特联合熊去氧胆酸治疗单用熊..
非诺贝特联合熊去氧胆酸治疗单用熊去氧胆酸应答不佳的原发性胆汁性胆管炎患者的效果评价
Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone
文章发布日期:2018年09月30日  来源:  作者:王璐,孙可帅,韩者艺,等  点击次数:233次  下载次数:31次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的探讨非诺贝特联合熊去氧胆酸(UDCA)治疗单用熊去氧胆酸应答不佳的原发性胆汁性胆管炎(PBC)患者的效果。方法选取2009年5月-2017年12月于空军军医大学西京消化病医院就诊的UDCA应答不佳PBC患者67例,根据是否加用非诺贝特分为联合治疗组33例、UDCA单药治疗组34例。收集2组患者基线(UDCA治疗1年时)和治疗后第6、12个月的临床资料,对比2组患者治疗后血清生化指标、生化应答反应、GLOBE评分。正态分布的计量资料2组间比较采用t检验;非正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间比较采用χ2检验或Fisher精确检验分析。结果治疗后第12个月,联合治疗组血清ALP、AST、ALT和GGT水平较单药UDCA组明显降低,差异均有统计学意义(t值分别为3465、2406、2057、3208,P值分别为<0.001、0.019、0.002、0.044)。根据巴塞罗那标准、ParisⅠ、Ⅱ标准,联合治疗组治疗12个月后的生化应答率分别为54.5%(18/15)、36.4%(12/21)、343%(11/22),巴塞罗那标准的评价结果与单药治疗组比较差异有统计学差异(t=4.349,P=0037)。治疗第12个月时,联合治疗组的GLOBE评分明显低于单药治疗组[0921(0519~1657)vs 0498(-0026~1027),Z=-2.007,P=0045],5、10、15年非肝移植生存率明显高于单药治疗组,差异有统计学意义(Z值分别为-2000、-2004、-2009,P值分别为0.045、0.045、0.043)。结论非诺贝特联合UDCA可以明显改善UDCA应答不佳患者的血生化指标,尤其是血清ALP水平;同时可降低应答不佳者的GLOBE评分,可能有助于改善远期预后。
【Abstract】:ObjectiveTo investigate the clinical effect of fenofibrate combined with ursodeoxycholic acid (UDCA) in the treatment of primary biliary cholangitis (PBC) patients with poor response to UDCA alone. MethodsA total of 67 PBC patients with poor response to UDCA who were treated in Xijing Hospital of Digestive Diseases, Air Force Medical University, from May 2009 to December 2017 were enrolled, and according to whether fenofibrate was used in addition, they were divided into combination treatment group with 33 patients and UDCA group with 34 patients. Related clinical data at baseline (after one year of UDCA treatment) and at 6 and 12 months after treatment were collected, and the two groups were compared in terms of serum biochemical parameters, biochemical response, and GLOBE score after treatment. The t-test was used for comparison of normally distributed continuous data between two groups; the Mann-Whitney U test was used for comparison of continuous data with skewed distribution between two groups. The chi-square test or the Fisher′s exact test was used for comparison of categorical data between groups. ResultsCompared with the UDCA group at 12 months after treatment, the combination treatment group had significant reductions in the serum levels of alkaline phosphatase (ALP), aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transpeptidase (t=3465,2406,2057 and 3208, P<0.001 and P=0.019, 0.002, and 0.044). According to the Barcelona criteria and the Paris I/II criteria, the combination treatment group had a biochemical response rate of 54.5% (18/15), 36.4% (12/21), and 34.3% (11/22), respectively, and there was a significant difference in the evaluation results of the Barcelona criteria between the two groups (t=4349,P=0.037). Compared with the UDCA group at 12 months after treatment, the combination treatment group had a significantly lower GLOBE score[0921(0519~1657)vs 0498(-0026~1027),Z=-2007,P=0045] and significantly higher 5-, 10-, and 15-year transplant-free survival rates (Z=-2000,-2004 and -2009, P= 0.045, 0045, and 0043). ConclusionIn patients with poor response to UDCA alone, fenofibrate combined with UDCA can significantly improve their blood biochemical parameters, especially the serum level of ALP. The combination treatment can also reduce the GLOBE score in patients with poor response and thus may help to improve long-term prognosis.
【关键字】:肝硬化, 胆汁性; 熊脱氧胆酸; 非诺贝特; 治疗
【Key words】:liver cirrhosis, biliary; ursodesoxycholic acid; fenofibrate; therapy
【引证本文】:WANG L, SUN KS, HAN ZY, et al. Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone[J]. J Clin Hepatol, 2018, 34(11): 2368-2372. (in Chinese) 王璐, 孙可帅, 韩者艺, 等. 非诺贝特联合熊去氧胆酸治疗单用熊去氧胆酸应答不佳的原发性胆汁性胆管炎患者的效果评价[J]. 临床肝胆病杂志, 2018, 34(11): 2368-2372.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号